These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 17416416)

  • 1. The incidence and survival of Waldenström's Macroglobulinaemia in South East England.
    Phekoo KJ; Jack RH; Davies E; Møller H; Schey SA;
    Leuk Res; 2008 Jan; 32(1):55-9. PubMed ID: 17416416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Waldenström's macroglobulinemia: incidence patterns in the United States, 1988-1994.
    Groves FD; Travis LB; Devesa SS; Ries LA; Fraumeni JF
    Cancer; 1998 Mar; 82(6):1078-81. PubMed ID: 9506352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 20-year retrospective study of tonsil cancer incidence and survival trends in South East England: 1987-2006.
    Olaleye O; Moorthy R; Lyne O; Black M; Mitchell D; Wiseberg J
    Clin Otolaryngol; 2011 Aug; 36(4):325-35. PubMed ID: 21696555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the incidence and mortality of vulval cancer in women in South East England 1960-1999.
    Somoye GO; Mocroft A; Olaitan A
    Arch Gynecol Obstet; 2009 Feb; 279(2):113-7. PubMed ID: 18488239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in the incidence and survival of cancer in teenagers and young adults: regional analysis for South East England 1960-2002.
    Croucher C; Whelan JS; Møller H; Davies EA
    Clin Oncol (R Coll Radiol); 2009 Jun; 21(5):417-24. PubMed ID: 19375901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Colorectal cancer incidence, mortality and survival in South-east England between 1972 and 2001.
    Sanjoaquin MA; Choodari-Oskooei B; Dolbear C; Putcha V; Sehgal A; Key TJ; Møller H
    Eur J Cancer Prev; 2007 Feb; 16(1):10-6. PubMed ID: 17220699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Smouldering Waldenstrom's macroglobulinemia: factors predicting evolution to symptomatic disease.
    Cesana C; Miqueleiz S; Bernuzzi P; Tresoldi E; Rossi V; D'avanzo G; Filippini D; Morra E
    Semin Oncol; 2003 Apr; 30(2):231-5. PubMed ID: 12720142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of clinical presentation, treatment, and outcome in patients with Waldenstrom's macroglobulinemia: a two-institution study.
    Björkholm M; Johansson E; Papamichael D; Celsing F; Matthews J; Lister TA; Rohatiner AZ
    Semin Oncol; 2003 Apr; 30(2):226-30. PubMed ID: 12720141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Asymptomatic Waldenstrom's macroglobulinemia.
    Alexanian R; Weber D; Delasalle K; Cabanillas F; Dimopoulos M
    Semin Oncol; 2003 Apr; 30(2):206-10. PubMed ID: 12720137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of lymphoplasmacytic lymphoma/Waldenström's macroglobulinaemia in Japan and Taiwan population-based cancer registries, 1996-2003.
    Iwanaga M; Chiang CJ; Soda M; Lai MS; Yang YW; Miyazaki Y; Matsuo K; Matsuda T; Sobue T
    Int J Cancer; 2014 Jan; 134(1):174-80. PubMed ID: 23784625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia.
    Ghobrial IM; Fonseca R; Gertz MA; Plevak MF; Larson DR; Therneau TM; Wolf RC; Hoffmann RJ; Lust JA; Witzig TE; Lacy MQ; Dispenzieri A; Vincent Rajkumar S; Zeldenrust SR; Greipp PR; Kyle RA
    Br J Haematol; 2006 Apr; 133(2):158-64. PubMed ID: 16611306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
    Kyle RA; Treon SP; Alexanian R; Barlogie B; Björkholm M; Dhodapkar M; Lister TA; Merlini G; Morel P; Stone M; Branagan AR; Leblond V
    Semin Oncol; 2003 Apr; 30(2):116-20. PubMed ID: 12720119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathologic spectrum of Waldenström's macroglobulinemia: a single center experience.
    Sajid R; Siddiqui SH; Shaikh U; Adil S
    Indian J Pathol Microbiol; 2010; 53(3):490-3. PubMed ID: 20699509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK.
    Phekoo KJ; Schey SA; Richards MA; Bevan DH; Bell S; Gillett D; Møller H;
    Br J Haematol; 2004 Nov; 127(3):299-304. PubMed ID: 15491289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential diagnosis of Waldenstrom's macroglobulinemia from other low-grade B-cell lymphoproliferative disorders.
    Pangalis GA; Kyrtsonis MC; Kontopidou FN; Vassilakopoulos TP; Siakantaris MP; Dimopoulou MN; Kittas C; Angelopoulou MK
    Semin Oncol; 2003 Apr; 30(2):201-5. PubMed ID: 12720136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphoplasmacytic lymphoma-Waldenstrom's macroglobulinemia.
    Vitolo U; Ferreri AJ; Montoto S
    Crit Rev Oncol Hematol; 2008 Aug; 67(2):172-85. PubMed ID: 18499469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Waldenström macroglobulinemia. Development of diagnostic criteria and identification of prognostic factors.
    Owen RG; Barrans SL; Richards SJ; O'Connor SJ; Child JA; Parapia LA; Morgan GJ; Jack AS
    Am J Clin Pathol; 2001 Sep; 116(3):420-8. PubMed ID: 11554171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance?
    Gobbi PG; Baldini L; Broglia C; Goldaniga M; Comelli M; Morel P; Morra E; Cortelazzo S; Bettini R; Merlini G
    Clin Cancer Res; 2005 Mar; 11(5):1786-90. PubMed ID: 15756000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors in Waldenstrom's macroglobulinemia: description of the complications during the evolution-preliminary results on 101 patients.
    Stalnikiewicz L; Carrotte-Lefebvre I; Detourmignies L; Rose C; Cazin B; Leblond V; Morel P
    Semin Oncol; 2003 Apr; 30(2):216-9. PubMed ID: 12720139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The incidence and epidemiology of plasma cell neoplasms.
    Bergsagel D
    Stem Cells; 1995 Aug; 13 Suppl 2():1-9. PubMed ID: 8520495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.